Floatz logo

Leucine

Frontotemporal Dementia (FTD MAPT Mutation)

Washington University School of MedicineSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Frontotemporal Dementia (FTD MAPT Mutation) cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Mayo Clinic
Phase 4BBB
FLUDEOXYGLUCOSE
University of Michigan
Phase 4BB
CITALOPRAM
Sunnybrook Health Sciences Centre
Phase 4BB
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 4BB
LEMBOREXANT
Nova Scotia Health Authority
Phase 4BB

View all 41 →

Same molecule, other indications

Leucine is also rated in:

obesity disorderDormant
CC
Indicative ·
46 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →
hyperglycemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →